Christine Ocampo Net Worth

The estimated Net Worth of Christine Ocampo is at least $720 Thousand dollars as of 10 May 2017. Ms. Ocampo owns over 10,010 units of Urovant Sciences Ltd stock worth over $233,388 and over the last 8 years she sold UROV stock worth over $0. In addition, she makes $486,564 as Senior Vice President, Chief Accounting Officer, and Principal Accounting Officer at Urovant Sciences Ltd.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Ocampo UROV stock SEC Form 4 insiders trading

Christine has made over 1 trades of the Urovant Sciences Ltd stock since 2017, according to the Form 4 filled with the SEC. Most recently she bought 10,010 units of UROV stock worth $100,000 on 10 May 2017.

The largest trade she's ever made was buying 10,010 units of Urovant Sciences Ltd stock on 10 May 2017 worth over $100,000. On average, Christine trades about 1,430 units every 0 days since 2017. As of 10 May 2017 she still owns at least 21,590 units of Urovant Sciences Ltd stock.

You can see the complete history of Ms. Ocampo stock trades at the bottom of the page.

Christine Ocampo biography

Christine G. Ocampo, CPA., serves as Senior Vice President, Chief Accounting Officer, Principal Accounting Officer of the Company. From September 2015 to May 2017, Ms. Ocampo was the Senior Vice President and Chief Financial Officer of Otic Pharma, Ltd., until it was acquired by Novus Therapeutics, after which she served as the Chief Financial and Compliance Officer until July 2017, and as a consultant from July 2017 to October 2017. Ms. Ocampo has over 20 years of accounting and finance experience, including over 11 years as the head of Finance for publicly traded companies in the healthcare industry. From 2007 to September 2015, Ms. Ocampo served in various roles at Avanir, including Vice President of Finance, Chief Accounting Officer and Vice President of Finance, Chief Compliance Officer and Secretary. From 2001 to 2006, Ms. Ocampo served as the Senior Vice President, Chief Financial Officer, Chief Accounting Officer, Treasurer, Secretary and Vice President, Corporate Controller of Cardiogenesis Corporation (now CryoLife, Inc.), a publicly traded medical device company. From 1996 to 1997, Ms. Ocampo held a management role in Finance at Mills-Peninsula Health Systems in Burlingame, California, and from 1994 to 1996, served as an auditor for Ernst & Young LLP. Ms. Ocampo earned a B.A. in Accounting from Seattle University and is a licensed Certified Public Accountant in the state of Washington.

What is the salary of Christine Ocampo?

As the Senior Vice President, Chief Accounting Officer, and Principal Accounting Officer of Urovant Sciences Ltd, the total compensation of Christine Ocampo at Urovant Sciences Ltd is $486,564. There are 3 executives at Urovant Sciences Ltd getting paid more, with Cornelia Haag-Molkenteller having the highest compensation of $1,703,470.

How old is Christine Ocampo?

Christine Ocampo is 46, she's been the Senior Vice President, Chief Accounting Officer, and Principal Accounting Officer of Urovant Sciences Ltd since 2019. There are 6 older and 1 younger executives at Urovant Sciences Ltd. The oldest executive at Urovant Sciences Ltd is Myrtle Potter, 61, who is the Chairman of the Board.

What's Christine Ocampo's mailing address?

Christine's mailing address filed with the SEC is C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE, CA, 92617.

Insiders trading at Urovant Sciences Ltd

Over the last 6 years, insiders at Urovant Sciences Ltd have traded over $0 worth of Urovant Sciences Ltd stock and bought 22,782,569 units worth $411,146,115 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ..., and Andrew Lo. On average, Urovant Sciences Ltd executives and independent directors trade stock every 6 days with the average trade being worth of $6,293,420. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 19 February 2020, trading 103,250 units of UROV stock currently worth $1,350,510.

What does Urovant Sciences Ltd do?

Complete history of Ms. Ocampo stock trades at Novus Therapeutics Inc and Urovant Sciences Ltd

Urovant Sciences Ltd executives and stock owners

Urovant Sciences Ltd executives and other stock owners filed with the SEC include:

• Cornelia Haag-Molkenteller,
  Chief Medical Officer of USI
• Bryan Smith,
  General Counsel - USI
• Michael McFadden,
  Chief Commercial Officer
• Christine Ocampo,
  Senior Vice President, Chief Accounting Officer, Principal Accounting Officer
• Kenton Stewart,
  Senior Vice President of Market Access
• Walt Johnston,
  Senior Vice President of Commercial
• James Hindman,
  Director
• Shigeyuki Nishinaka,
  Director
• Ajay Bansal,
  Chief Financial Officer, Senior Vice President - Business Development, Principal Financial Officer
• Myrtle Potter,
  Chairman of the Board
• James Robinson,
  Principal Executive Officer, Director
• Pierre Legault,
  Independent Director
• Sef Kurstjens,
  Independent Director
• Holdings Ltd.Dexcel Pharma ...,
  
• Associates Gp Llcqvt Fund V...,
  
• Patrick Machado,
  
• Frank Torti,
  Director
• Global Investors Lp Viking ...,
  
• Investments (Uk) Ltd Soft B...,
  
• Nori Ebersole,
  SVP&CHRO-Urovant Sciences,Inc.
• Global Performance Llc Viki...,
  
• Sciences Ltd. Roivant,
  10% owner
• Andrew Lo,
  
• Global Performance Llc Viki...,
  
• Associates Gp Llcqvt Financ...,
  
• Chemical Co., Ltd.Sumitomo ...,
  
• Keith Katkin,
  PEO;CEO/Urovant Sciences, Inc.